Research Applications
Ischemic Stroke
CASTA trial (n=1,070) showed improved outcomes. Multiple meta-analyses support efficacy for acute ischemic stroke when combined with standard care.
Alzheimer's Disease
Cochrane review (2019) found modest cognitive improvement. Most studies from Europe and Asia.
Traumatic Brain Injury
Clinical studies show improved cognitive recovery and reduced disability.
Vascular Dementia
Evidence for improved cognitive function in vascular dementia patients.
Mechanism of Action
Cerebrolysin's neuropeptide components act on multiple neurotrophic signaling pathways simultaneously. They activate TrkB (BDNF-like), TrkA (NGF-like), and Ret (GDNF-like) receptor systems, promoting neuronal survival, synaptic plasticity, and neurogenesis. The preparation also inhibits calpain-mediated neurodegeneration, reduces amyloid-beta aggregation, and suppresses GSK-3β (reducing tau phosphorylation).
Biological Pathways
BDNF/TrkB/MAPK/CREB for neuroplasticity. NGF/TrkA for cholinergic support. PI3K/Akt for neuronal survival. Calpain inhibition for neuroprotection. GSK-3β suppression for tau regulation.
Dosage Information
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
No protocols featuring this peptide yet.
Browse All ProtocolsStability & Storage
Supplied as aqueous solution (215.2 mg/mL) in ampoules. Store at room temperature (up to 25°C). Protect from light. Shelf life 5 years. Administered intravenously — requires dilution in saline.
Side Effects & Precautions
Dizziness (7%), headache, nausea, injection site reactions. Fever and agitation rarely. Generally well-tolerated in large clinical trials. Contraindicated in epilepsy and severe renal impairment.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Regulatory Status
Approved in >50 countries (Europe, Asia, Latin America) for stroke, TBI, and dementia. NOT FDA-approved — not available in the US. EMA-registered. Requires IV administration in clinical settings.
Research Studies
Cerebrolysin in Acute Ischemic Stroke (CASTA)
Heiss WD, Brainin M, Bornstein NM, et al.
Cerebrolysin for Alzheimer's Disease (Cochrane Review)
Gauthier S, Proano JV, Jia J, et al.
